Short Interest in Liminatus Pharma Inc. (NASDAQ:LIMN) Increases By 182.1%
by Renee Jackson · The Cerbat GemLiminatus Pharma Inc. (NASDAQ:LIMN – Get Free Report) was the target of a large growth in short interest in the month of April. As of April 15th, there was short interest totaling 1,989,468 shares, a growth of 182.1% from the March 31st total of 705,229 shares. Based on an average daily volume of 13,534,680 shares, the days-to-cover ratio is presently 0.1 days. Approximately 4.4% of the company’s stock are sold short.
Liminatus Pharma Trading Down 0.8%
Shares of Liminatus Pharma stock traded down $0.00 during trading on Friday, reaching $0.20. The stock had a trading volume of 633,993 shares, compared to its average volume of 8,438,084. The company has a market capitalization of $8.89 million and a price-to-earnings ratio of -1.32. Liminatus Pharma has a 52 week low of $0.16 and a 52 week high of $33.66. The stock has a fifty day moving average price of $0.22 and a two-hundred day moving average price of $0.71.
Liminatus Pharma (NASDAQ:LIMN – Get Free Report) last released its quarterly earnings results on Tuesday, March 31st. The company reported ($0.34) earnings per share for the quarter.
Wall Street Analyst Weigh In
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Liminatus Pharma in a report on Friday, March 27th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Liminatus Pharma presently has an average rating of “Sell”.
Read Our Latest Stock Report on LIMN
Liminatus Pharma Company Profile
Liminatus Pharma, Inc is a pre-clinical-stage immuno-oncology company, which engages in developing novel, immune-modulating cancer therapies. The company was founded on November 1, 2020 and is headquartered in La Palma, CA.